natgillin/translations-raw huggingface dataset:
Besilesomab is a murine immunoglobulin of IgG1 isotype that specifically binds to NCA-95 (non specific cross-reacting antigen 95), an epitope expressed at the cell membrane of granulocytes and granulocyte precursors. 
Mehanizem delovanja Besilesomab je mišji imunoglobulin izotipa IgG1, ki se specifično veže na NCA-95 (nespecifični navzkrižno reaktivni antigen 95), epitop, ki se izraža na celični membrani granulocitov in granulocitnih prednikov.
False results may be obtained in patients with diseases involving neutrophil defects and to patients with haematological malignancies including myeloma. 
Rezultati so lahko lažno pozitivni pri bolnikih z boleznimi z okvarami nevtrofilcev in pri bolnikih s hematološkimi malignimi boleznimi, vključno z mielomom.
Such substances should therefore not be administered together with, or a short time before the injection of Scintimun. 
Takšnih snovi zato ne morete dajati sočasno z zdravilom Scintimun ali v kratkem času pred injiciranjem tega zdravila.
Swirl carefully; the content of the vial of Scintimun will dissolve within one minute (DO NOT shake). 
Previdno vrtinčite, da se vsebina viale z oznako Scintimun raztopi v roku ene minute (NE
The activity must be between 400 and 1800 MBq depending on the volume of pertechnetate (99mTc). 
Aktivnost mora biti med 400 in 1800 MBq, odvisno od volumna pertehnetata (99mTc).
Method Instant thin layer chromatography or paper chromatography. 
Metoda Hitra tankoplastna kromatografija ali papirno kromatografijo
Data on repeated dosing of Scintimun are very limited. 
Podatkov o ponavljajočem se odmerjanju zdravila Scintimun je zelo malo.
What Scintimun is and what it is used for What you need to know before you are given Scintimun How Scintimun is given 
Kaj je zdravilo Scintimun in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Scintimun Kako boste prejeli zdravilo Scintimun
Twenty-four hours after injection, the percentages of radioactivity are 1.6 % in the liver and 2.3 % in the spleen. 
Štiriindvajset ur po injiciranju je v jetrih 1,6 % radioaktivnosti, v vranici pa 2,3 %.
Cut the strip in two separate parts at Rf = 0.5. 
Na Rf = 0,5 prerežite trak v dva ločena dela.
However, based on the investigator's diagnosis after one month of follow-up, Scintimun had a slightly lower specificity (71.8 %) than 99mTc-WBCs (79.5 %). 
Vendar je imelo zdravilo Scintimun na osnovi diagnoze raziskovalcev po enem mesecu sledenja nekoliko manjšo specifičnost (71,8 %) kot s 99mTc označeni levkociti (79,5 %).
Besilesomab is an anti-granulocyte monoclonal antibody (BW 250/183), produced in murine cells. 
Besilesomab je monoklonsko protitelo proti granulocitom (BW 250/183), izdelano v mišjih celicah.
Calculations 
Izračuni
Development of human anti-mouse antibodies reacting against the antibody in Scintimun (antibody of the mouse cells) with a risk of allergic reaction 
nastajanje človeških protiteles proti mišjim protitelesom, ki reagirajo proti protitelesom v zdravilu Scintimun (protitelesom iz mišjih celic), s tveganjem alergijske reakcije.
Without removing the needle, withdraw an equivalent volume of air in order to avoid excess pressure in the vial. 
Igle ne izvlecite, ampak v brizgo povlecite enak volumen zraka, da ohranite atmosferski tlak v viali.
Technetium (99mTc) is produced by means of a (99Mo/99mTc) generator and decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.02 hours to technetium (99Tc) which, in view of its long half-life of 2.13 x 105 years can be regarded as quasi stable. 
Tehnecij (99mTc) nastaja v generatorju (99Mo/99mTc) in razpada z emisijo gama sevanja s povprečno energijo 140 keV in razpolovno dobo 6,02 ur v tehnecij (99Tc), ki se šteje za kvazistabilnega glede na dolgo razpolovno dobo 2,13 x 105 let.
Potential for hypersensitivity or anaphylactic reactions If hypersensitivity or anaphylactic reactions occur, the administration of the medicinal product must be discontinued immediately and intravenous treatment initiated, if necessary. 
Možnost preobčutljivostnih ali anafilaktičnih reakcij V primeru preobčutljivostnih ali anafilaktičnih reakcij je treba takoj prekiniti dajanje zdravila in po potrebi uvesti intravensko zdravljenje.
The nuclear medicine doctor supervising the procedure will decide on the quantity of technetium(99mTc)- besilesomab to be used in your case. 
Zdravnik nuklearne medicine, ki bo nadzoroval postopek, bo določil količino uporabljenega tehnecijevega (99m Tc) besilomaba v vašem primeru.
Technetium(99mTc) is a radioactive element allowing the organs where besilesomab accumulates to be seen using a special camera. 
Tehnecij (99mTc) je radioaktivni element, ki omogoča, da so organi z nakopičenim besilesomabom, vidni s posebno kamero.
Radiopharmaceuticals should be prepared in a manner which satisfies both radiation safety and pharmaceutical quality requirements. 
Radiofarmake je treba pripraviti v skladu z varnostjo pred sevanjem in zahtevami za kakovost farmacevtskega izdelka.
Hypersensitivity to the active substance, to other murine antibodies, to any of the excipients listed in section 6.1 or to any of the components of the labelled radiopharmaceutical. 
Preobčutljivost na zdravilno učinkovino, druga mišja protitelesa, katero koli pomožno snov, navedeno v poglavju 6.1, ali katere koli sestavine označenega radiofarmaka
Six hours after injection, about 1.5 % of the whole body radioactivity is found in the liver whereas about 3.0 % is found in the spleen. 
Šest ur po injiciranju najdemo približno 1,5 % radioaktivnosti iz polne krvi v jetrih, približno 3,0 % pa v vranici.
Duration of the procedure Your Nuclear medicine doctor will inform you about the usual duration of the procedure. 
O običajni dolžini postopka vas obvesti zdravnik nuklearne medicine.
After disinfecting the stopper, the solution should be withdrawn via the stopper using a single dose syringe fitted with suitable protective shielding and a disposable sterile needle or using an authorised automated application system. 
raztopino pa morate odvzeti prek zamaška z enoodmerno injekcijsko brizgo, opremljeno z ustrezno zaščito in sterilno iglo za enkratno uporabo, ali z uporabo odobrenega avtomatskega sistema apliciranja.
After the procedure 
Po postopku
Administration procedures should be carried out in a way to minimise risk of contamination of the medicinal product and irradiation of the operators. 
Postopke dajanja je treba izvajati tako, da se čim bolj zmanjša tveganje za okužbo zdravila in obsevanje osebja.
DO NOT let the spot dry. 
PAZITE, da se nanos ne posuši.
After complete dissolution, disinfect the septum and allow drying. 
Po popolni raztopitvi septum razkužite in počakajte, da se posuši.
- If you have any further questions, ask your doctor or the nuclear medicine specialist who will supervise the procedure. 
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali specialistom nuklearne medicine, ki bo nadzoroval postopek.
Before administering radiopharmaceuticals to a mother who is breast-feeding, consideration should be given to the possibility of delaying the administration of radionuclide until the mother has ceased breast-feeding and to what is the most appropriate choice of radiopharmaceuticals, bearing in mind the secretion of activity in breast milk. 
Pred uporabo radiofarmakov pri doječi materi morate ugotoviti, ali je možno dajanje radionuklida odložiti, dokler preiskovanka ne preneha z dojenjem oz. kateri so najbolj primerni radiofarmaki ob upoštevanju izločanja aktivnosti v materinem mleku.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodiumfree'. 
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar pomeni, da je v bistvu „brez natrija“.
Preclinical data obtained with the non-radioactive compound reveal no special hazard for humans based on conventional studies of safety pharmacology, single-dose and repeated-dose toxicity, although antimurine antibodies were found in all dose groups (including controls) in a repeated-dose study in monkeys. 
Predklinični podatki, dobljeni z neradioaktivno spojino, na osnovi običajnih študij farmakološke varnosti ter toksičnosti enega odmerka in pri ponavljajočih se odmerkih ne kažejo posebnega tveganja za človeka, čeprav so v študiji s ponavljajočimi se odmerki pri opicah odkrili protitelesa proti mišjim protitelesom v vseh skupinah z različnimi odmerki (tudi v kontrolni skupini).
Contents of the vial are intended only for use in the preparation of technetium(99mTc) besilesomab and are not to be administered directly to the patient without first undergoing the preparative procedure. 
Vsebina viale je indicirana samo za uporabo pri pripravi tehnecijevega (99mTc) besilesomaba in ni primerna za neposredno dajanje brez predhodne priprave bolnika.
However, in the case of an overdose, you will be asked to drink plenty of water and to take laxatives to increase the elimination of the product from your body. 
Če pa prejmete prevelik odmerek, vam bodo naročili pitje obilo vode ter uporabo odvajal, da se bo povečalo odstranjevanje zdravila iz telesa.
In the event of administration of a radiation overdose with technetium (99mTc) besilesomab, the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by forced diuresis and frequent bladder voiding, and by the use of laxatives to promote faecal excretion. 
V primeru uporabe prevelikega odmerka sevanja s tehnecijevim (99mTc) besilesomabom je treba odmerek, ki ga je absorbiral preiskovanec, če je mogoče čimbolj zmanjšati, s povečanjem izločanja radionuklida iz telesa s prisilno diurezo in pogostim praznjenjem mehurja ter uporabo odvajal za pospeševanje izločanja blata.
Elderly No dose adjustment is required. 
Starostniki Prilagajanje odmerka ni potrebno.
Besilesomab has no effect on activation of complement, granulocyte function or platelets. 
Besilesomab nima učinka na aktivacijo komplementa, na funkcijo granulocitov in trombocite.
Dispose of radioactive waste in accordance with local regulations. 
Radioaktivni odpadni material zavrzite v skladu z lokalnimi predpisi.
Using a hypodermic syringe, introduce through the rubber seal 2-7 mL of pertechnetate (99mTc) (the eluate complies with the requirements of current Eur. 
S hipodermijsko brizgo skozi zamašek iz kavčuka vnesite 2-7 ml pertehnetata (99mTc) (izpirek ustreza zahtevam veljavne Eur.
In the most recent clinical study in which 123 patients were administered Scintimun, the most commonly reported adverse reaction was the development of anti-mouse antibodies (HAMA) in 14 % of the patients, after a single administration (16 positive over 116 assayed one and/or three months after the administration). 
4.8 Neželeni učinki V večini nedavnih kliničnih študij, v katerih je 123 preiskovancev prejelo zdravilo Scintimun, je bila najpogosteje ugotovljen neželeni učinek nastanek humanih protiteles proti mišjim protitelesom (HAMA) pri 14 % preiskovancev po eni uporabi (16 pozitivnih od 116 testiranih en in/ali tri mesece po uporabi zdravila).
This radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk of cancer and hereditary abnormalities. 
S tem radiofarmakom prejmete majhne količine ionizirajočega sevanja, ki je povezano z zelo majhnim tveganjem za razvoj raka in dednih nepravilnosti.
Using a syringe, introduce through the rubber seal 5 mL of 0.9% sodium chloride solution. 
Z brizgo skozi zamašek iz kavčuka vnesite 5 ml 0,9-odstotne raztopine natrijevega klorida.
MedDRA System Organ Classes 
Skupine organskih sistemov po MedDRA
One mL of the radiolabelled solution contains less than 4 mg of sodium. 
En mililiter radioaktivno označene raztopine vsebuje manj kot 4 mg natrija.
The recommended activity of technetium (99mTc) besilesomab should be between 400 MBq and 
Priporočena aktivnost tehnecijevega (99mTc) besilesomaba mora biti med 400 MBq in 800 MBq.
MARKETING AUTHORISATION NUMBER(S) EU/1/09/602/001 one multidose vial Scintimun and one vial solvent for Scintimun EU/1/09/602/002 two multidose vials Scintimun and two vials solvent for Scintimun 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/09/602/001 ena večodmerna viala zdravila Scintimun in ena viala vehikla za zdravilo Scintimun
Scintimun contains sorbitol therefore patients with rare hereditary problems of fructose intolerance should not be administered this product. 
Zdravilo Scintimun vsebuje sorbitol, zato ga ne smejo prejeti preiskovanci z redko dedno intoleranco na fruktozno.
Should you have any further questions on the use of Scintimun, please ask the nuclear medicine doctor who supervises the procedure. 
Če imate dodatna vprašanja o uporabi zdravila Scintimun, se posvetujte z zdravnikom nuklearne medicine, ki je nadzoroval postopek.
Do not let air enter the vial to be tested and store all vials containing radioactive solution in lead shielding. 
Postopek Pazite, da zrak ne vstopi v vialo, ki jo boste preskusili, in da shranjujete vse viale z radioaktivno raztopino v svinčenih oklepih.
Human Anti-Mouse Antibodies (HAMA) 
Humana protitelesa proti mišjim protitelesom (HAMA)
(WBCs) images in 119 patients with suspected osteomyelitis, the agreement rate between the two methods was 83 % (lower 95 % confidence interval limit: 80 %). 
Stopnja ujemanja med metodama je bila 83 % (spodnja meja 95-odstotnega intervala zaupanja: 80 %).
Very common (may affect more than 1 in 10 people): 
Zelo pogosti (se lahko pojavijo pri več kot 1 od 10 bolnikov):
If the integrity of this vial is compromised, the product should not be used 
Če je integriteta viale ogrožena, zdravila ne smete uporabiti.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom nuklearne medicine, preden vzamete to zdravilo.Če obstaja možnost, da ste noseči, vam je izostala menstruacija ali dojite, o tem pred uporabo zdravila Scintimun obvestite zdravnika nuklearne medicine.
Administration of murine monoclonal antibodies can lead to the development of Human Anti-Mouse Antibodies (HAMA). 
Uporaba mišjih monoklonskih protiteles lahko povzroči nastanek humanih protiteles proti mišjim protitelesom (HAMA).
In vitro, besilesomab cross-reacts with CEA. 
Besilesomab navzkrižno reagira s CEA in vitro.
The radiochemical purity corresponds to the percentage of bound technetium (99mTc) and is calculated as follows after correcting data for background noise: 
Radiokemijska čistoča ustreza odstotku vezanega tehnecija (99mTc) in se po korekciji podatkov za izhodiščni šum izračuna po naslednjem postopku:
For storage conditions after reconstitution and radiolabelling of the medicinal product, see section 6.3. 
Za pogoje shranjevanja po rekonstituciji in radioaktivnem označevanju glejte poglavje 6.3.
Each vial of Scintimun contains 2 mg of sorbitol. 
Vsaka viala zdravila Scintimun vsebuje 2 mg sorbitola.
Other medicines and Scintimun 
Druga zdravila in zdravilo Scintimun
Introduce the ITLC-SG or RBM-1 paper strip immediately into the chromatography tank using forceps to avoid formation of pertechnetate (99mTc) due to oxygen. 
ITLC-SG ali RBM-1 papirnati trak nemudoma s pinceto prenesite v kromatografsko kopel, da preprečite nastanek pertehnetata (99mTc) zaradi kisika.
Bone marrow (red) Muscles 
Tanko črevo Kostni mozeg (rdeči)
However, after sodium pertechnetate (99mTc) is added, adequate shielding of the final preparation must be maintained. 
Ko se doda natrijev (99mTc) pertehnetat, pa je treba ves čas uporabljati ustrezen ščit pred sevanjem končnega pripravka.
Scintimun contains sorbitol and sodium 
Zdravilo Scintimun vsebuje sorbitol in natrij
The radiochemical purity (the percentage of bound Technetium (99mTc)) must be more than or equal to 95 %. 
Radiokemijska čistoča (odstotek vezanega tehnecija (99mTc)) mora biti vsaj 95 %.
Introduce the solvent into the chromatography tank to a depth of approximately 2 cm. Cover the tank and allow to equilibrate for at least 5 minutes. 
Prenesite topilo v kromatografsko kopel do višine približno 2 cm. Kopel pokrijte in omogočite,
Talk to the nuclear medicine specialist before using Scintimun: - if you have previously been administered Scintimun, because you should only be administered 
Pred začetkom uporabe zdravila Scintimun se posvetujte s specialistom nuklearne medicine: - če ste že kdaj prejeli zdravilo Scintimun, saj ga lahko prejmete le enkrat v življenju.
Because you could emit radiation especially harmful to young children during the first 12 hours after the injection, you should avoid close contact with young children and pregnant women during this period of time. 
Ker lahko v prvih 12 urah po injiciranju oddajate sevanje, ki je nevarno zlasti za otroke, se morate v tem času izogibati tesnim stikom z majhnimi otroki.
Possible side effects are listed in the order of their frequency below: 
Spodaj so našteti možni neželeni učinki po padajoči pogostnosti:
If the administration is considered necessary, breast-feeding should be interrupted for three days and the expressed feeds discarded. 
Če menite, da je uporaba radiofarmaka potrebna, je treba dojenje prekiniti za tri dni in iztisnjeno mleko zavreči.
In order to obtain images of best quality and to reduce the radiation exposure of your bladder, you should drink sufficient amounts and empty your bladder prior to and after the scintigraphic examination. 
Da bi dobili najkakovostnejše slike in zmanjšali izpostavitev sečnega mehurja sevanju, morate piti zadostne količine tekočin ter izprazniti sečni mehur pred in po scintigrafski preiskavi.
If you are breast-feeding you must stop breast-feeding for 3 days after your injection and the expressed milk should be discarded. 
Če dojite, morate za 3 dni po injiciranju prekinete z dojenjem in zavreči iztisnjeno mleko.
Organ mSv/MBq 
Organ mSv/MBq referenčni moški referenčna ženska
Radiation protection precautions in accordance with national regulations must therefore be taken. 
Zato je treba upoštevati morate ukrepe za zaščito pred sevanjem v skladu z lokalnimi predpisi.
In order to obtain images of best quality and to reduce the radiation exposure of the bladder, patients should be encouraged to drink sufficient amounts and to empty their bladder prior to and after the scintigraphic examination. 
Da bi dobili najkakovostnejše slike in zmanjšali izpostavitev sečnega mehurja sevanju, morate preiskovance spodbujati k pitju zadostnih količin tekočin ter k izpraznjenju sečnega mehurja pred in po scintigrafski preiskavi.
For each organ, or group of organs, the absorbed doses have been calculated using the methodology developed by the MIRD (Medical Internal Radiation Dose). 
Izračunani so absorbirani odmerki za vsak organ ali skupino organov z metodologijo MIRD (Medical
Inquiry on possible previous exposure to murine monoclonal antibodies and a HAMA test should be made prior to administration of Scintimun; a positive response would contraindicate the administration of Scintimun (see section 4.3). 
Pred uporabo zdravila Scintimun morate preiskovanca vprašati o morebitnih predhodnih izpostavitvah mišjim monoklonskim protitelesom in opraviti preiskavo za HAMA; pozitiven odziv oz. rezultat kontraindicira uporabo zdravila Scintimun (glejte poglavje 4.3).
For an administered activity of 800 MBq the typical radiation dose to the target organ bone is 14.2 mGy and the typical radiation doses to the critical organs, bone marrow, spleen and kidneys are 19.4 mGy, 21.7 mGy, and 16.8 mGy respectively. 
Za odmerjeno aktivnost 800 MBq je značilen odmerek sevanja za ciljni organ (kost) 2,0 mGy in značilen odmerek sevanja za kritične organe (kostni mozeg) je 19,4 mGy,
Transfer 1 mL of this solution with a hypodermic syringe into a vial of Scintimun (green crimped aluminium capsule). 
Prenesite 1 ml te raztopine s hipodermijsko brizgo v vialo z oznako Scintimun (z zelenim aluminijevim pokrovčkom).
This medicinal product should be reconstituted and radiolabelled before administration to the patient. 
Zdravilo je treba pred dajanjem bolniku rekonstituirati in nato radioaktivno označiti.
Scintimun is used for the preparation of a radioactive solution for injection of technetium(99mTc)besilesomab. 
Zdravilo Scintimun se uporablja za pripravo radioaktivne raztopine za injiciranje, ki vsebuje tehnecijev (99mTc) besilesomab.
Eluates should only be taken from a technetium (99mTc)-generator that has been eluted within the past 24 hours (i.e. with less than 24 h in-grow). 
- Uporabite lahko le izpirke iz generatorja tehnecija (99mTc), ki se je izpiral v zadnjih 24 urah (tj.
15 mL, colourless, type I glass vial, closed with chlorobutyl rubber stopper and aluminium crimped capsule (green) containing 5.02 mg of powder. 
15 ml viala iz brezbarvnega stekla tipa I, zaprta z zamaškom iz klorobutilnega kavčuka in aluminijevim pokrovčkom (zelenim), ki vsebuje 5,02 mg praška.
Administration of Scintimun and conduct of the procedure Scintimun is administered intravenously. 
Dajanje zdravila Scintimun in izvajanje postopka Zdravilo Scintimun se daje intravensko.
Repeated use 
Ponovna uporaba
Scintimun contains less than 1 mmol of sodium (23 mg) per vial, i.e. essentially ‘sodium- free'. 
Zdravilo Scintimun vsebuje manj kot 1 mmol natrija (23 mg) na vialo, kar v bistvu pomeni “brez natrija”.
Scintimun is a medicine containing an antibody (besilesomab) used to target specific cells called granulocytes (a type of white blood cells involved in the inflammation process) in your body. 
To protitelo je usmerjeno proti specifičnim celicam, ki jim pravimo granulociti (vrsta belih krvnih celic, ki sodeluje pri vnetjih), v vašem telesu.
Disinfect the septum and allow drying. 
Razkužite septum in počakajte, da se posuši.
Positive screening test for human anti-mouse antibody (HAMA). 
Pozitivni presejalni test za humana protitelesa proti mišjim protitelesom (HAMA).
The active substance is besilesomab (anti-granulocyte monoclonal antibody from mouse origin). 
- Zdravilna učinkovina je besilesomab (monoklonsko protitelo mišjega izvora proti granulocitom).
Interpretation of images 
Interpretacija slik
Scintimun should be given to sufficiently hydrated patients. 
Priprava bolnika Zdravilo Scintimun dajemo zadostno hidriranim preiskovancem.
For instructions on reconstitution and radiolabelling of the medicinal product before administration, see section 12. 
Za navodila o rekonstituciji in radioaktivnem označevanju zdravila pred dajanjem glejte poglavje 12.
Notes on the instructions - Solvent for Scintimun must NEVER be radiolabelled first and then added to Scintimun. 
Opombe v zvezi z navodili: - Vehikla za zdravilo Scintimun ne smete NIKOLI radioaktivno označiti pred dodatkom zdravila
Scintimun should not be used for the diagnosis of diabetic foot infection. 
Zdravilo Scintimun se ne sme uporabljati za diagnozo okužbe diabetičnega stopala.
The activity administered should in every case be as low as reasonably achievable to obtain the required diagnostic information. 
Pri posameznem bolniku mora biti izpostavitev sevanju utemeljena s pričakovano koristjo.Uporabljena aktivnost mora biti v vsakem primeru tista najmanjša, s katero je še mogoče pridobiti potrebne diagnostične informacije.
Place the vial of Scintimun in an appropriate lead shielding container. 
Vialo z oznako Scintimun položite v ustrezno posodo s svinčenim oklepom.
Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials. 
Radiofarmaki se shranjujejo v skladu z nacionalnimi predpisi za radioaktivne materiale.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
Storage of radiopharmaceuticals should be in accordance with national regulation on radioactive materials. 
Shranjevanje radiofarmakov mora biti v skladu s predpisi o radioaktivnih snoveh.
Scintimun once in your lifetime. 
Scintimun še enkrat.